

**JOURNAL OF CARCINOGENESIS**  
A peer reviewed journal in the field of  
**Carcinogenesis and Carcinoprevention**

For the Researchers By the Researchers Of the Researchers

**Publish in the special issue on**

**Breast Carcinogenesis and Prevention**

**Edited by experts in the field**




**Vimla Band, Ph.D.** is Ardith and Anna Von Housen Professor and Chair of the department of Genetics, Cell Biology and Anatomy at the university Nebraska Medical Center. She also serves as an Associate Director of Center for Breast Cancer Research at UNMC-Eppley Cancer Center. Dr Band has been conducting NIH funded research for more than two decades to understand the pathways that convert normal mammary epithelial cells to cancerous cells. The major focus of her laboratory is to delineate molecular mechanisms of early steps in transformation of mammary epithelial cells with the goal of identifying novel molecular diagnostic/prognostic markers and potential therapy targets of breast cancers. Recently, her laboratory has identified precursor cells for different subtypes of breast cancers and several novel cellular proteins that are involved in mammary epithelial cell transformation. Dr Band has published more than 100 peer-reviewed publications in prestigious journals, such as Proceedings of National Academy of Sciences, Molecular and Cellular Biology, Journal of Biological Chemistry and Cancer Research.



**Khandan Keyomarsi, Ph.D.** is a Professor in the Department of Experimental Radiation Oncology and Hubert L. and Olive Stringer Professor in Medical Oncology, at MD Anderson Cancer Center, Houston, TX. As a post-doctoral fellow, Dr. Keyomarsi made the seminal observations that cyclins are deregulated in breast cancer and that they can be novel targets for therapy. She continues her studies in this area and has become well known as well funded investigator for her research on this topic. Her team also identified cyclin E as a powerful prognostic indicator in breast cancer as well as a therapeutic target. Her laboratory is currently devising novel therapeutic strategies to protect normal cells against the toxic effects of chemotherapeutic agents in vivo, using animal models. She received training from prestigious institutions like the University of Southern California, Dana-Farber Cancer Institute and Harvard Medical School. Dr. Keyomarsi has published more than 85 peer-reviewed articles, numerous book chapters, invited articles and editorials. She serves on the editorial board for several journals and has served on multiple study sections. Dr. Keyomarsi has been invited to present at over 50 national and international conferences.



**David A. Potter, M.D., Ph.D.**, is an associate professor in the Department of Medicine at the university of Minnesota. He is also a member of the Women's Cancer Research Program at the Masonic Cancer Center. After undergraduate studies in biology at M.I.T., he received the M.D. and Ph.D. degrees from the Johns Hopkins University. He trained in internal medicine at Stanford University Medical Center, and in hematology and oncology at Tufts-New England Medical Center. Dr. Potter's research interests include studies on the roles of calpain proteases in cancer, the role of heat shock protein 90 (hsp 90) in breast cancer, and translational breast cancer clinical trials. He is also studying regulation of calpain proteases and the role in cytoskeletal remodeling; the role of cytochrome P450 in breast cancer progression. His research has been funded by NIH, and other agencies. He published several research papers in prestigious journals like Oncogene, Molecular Cell Biology, clinical cancer research.



**JOURNAL OF CARCINOGENESIS**  
A peer reviewed journal in the field of  
**Carcinogenesis and Carcinoprevention**

For the Researchers By the Researchers Of the Researchers

**Publish in the special issue on**  
**Breast Carcinogenesis and Prevention**  
**Edited by experts in the field**

**Submission Process:**

Prospective authors are invited to submit their manuscript through the Journal of Carcinogenesis online manuscript submission system located at <http://www.carcinogenesis.com/>. The authors are advised to adhere to the journal manuscript polices available. . The manuscripts undergo a double blinded peer review process and quality screening according to *Journal of Carcinogenesis* acceptance policy. *Journal of Carcinogenesis* levies an article-processing charge for every accepted article. Partial or comprehensive waiver of the article-processing charge may be granted to very high quality research based on recommendations from the guest editors.

**Deadlines:**

Deadline for manuscript submission: February 15, 2011

Publication Date: May 1, 2011.

For further inquiries about the submission or the review process contact [editor@carcinogenesis.com](mailto:editor@carcinogenesis.com)